JAMA Network
About The Study: In this secondary analysis of the WISDOM trial, a randomized clinical trial that enrolled women without breast cancer ages 40 to 74, criteria-independent genetic testing in a pragmatic trial identified a substantial number of women with clinically actionable results, many of whom would not have qualified for genetic
testing under current guidelines. These findings support broader access to genetic testing as part of personalized breast cancer risk assessment.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
